Powerful Nonnarcotic Analgesic Cleared By FDA
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Powerful Nonnarcotic Analgesic Cleared By FDA

PHILADELPHIA, PA -- July 16, 1997 -- Duract(TM) (bromfenac sodium capsules), a potent nonnarcotic analgesic that belongs to the nonsteroidal anti-inflammatory drug (NSAID) class, was cleared for marketing yesterdayby the U.S. Food and Drug Administration (FDA), said Wyeth-Ayerst Laboratories, a division of American Home Products Corporation, announced today.

The availability of Duract(TM) marks an important development for health care providers whose patients need fast-acting and powerful relief from acute pain, but want to avoid many of the performance-impairing side effects that can accompany a narcotic opioid analgesic.

"This new medication should be a welcome relief for people whose activities have been compromised by acute pain," says Marc W. Deitch, M.D., Senior Vice President, Medical Affairs and Medical Director for Wyeth-Ayerst Laboratories. "Duract(TM) (bromfenac sodium capsules) can provide pain sufferers significant relief from their pain without the combined worry of opioid side effects and the potential for chemical dependency."

Today's FDA marketing clearance follows a series of clinical studies that demonstrate the effectiveness of Duract in the management of acute pain in a wide range of applications, such as postoperative use following major abdominal, gynecologic, oral, or orthopedic surgery.

The most frequent complaints with Duract(TM) use relate to minor gastrointestinal problems. In some patients treated with Duract, serious gastrointestinal toxicity such as perforation, ulceration, and bleeding can occur. In addition, elevations of liver enzymes have been reported. Therefore, while Duract(TM) is indicated for the short-term management of pain, generally less than 10 days duration, if a physician chooses to administer Duract for a longer duration, it is recommended that liver enzymes should be monitored in patients treated for more than four weeks.

More information on: Wyeth-Ayerst Laboratories, More information on: American Home Products Corporation

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities